Atezolizumab for tumors that look sensitive on DNA/RNA testing
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an incurable solid tumor and already had tumor DNA and RNA testing done through a program like POG (or a similar one), and your results placed you into an open trial cohort.
- Your overall health score (ECOG) is 0–2.
- Your cancer has measurable disease on scans, and you’re expected to live at least 12 weeks.
- Your blood and organ tests (kidneys, liver, and blood counts) meet specific minimum levels from bloodwork done within 28 days before starting.
- You can safely take the study drug and sign informed consent; if you’re pregnant/breastfeeding you can’t join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
This trial studies a two-drug treatment (cabozantinib plus atezolizumab) for people with advanced or metastatic non-small cell lung cancer (NSCLC). It may help control the cancer and shrink tumors, especially for patients whose tumor tests show low PD-L1 and who fit the trial’s prior-treatment rules.
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
This trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with available therapies. It may be an option if your tumor has certain immune-related markers.
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
This Phase 2 trial tests the cancer medicines atezolizumab and tiragolumab in people with different solid tumors. It aims to see how well these drugs work and what side effects they cause in specific patient groups.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.